Monitor the IND submission for the CMAP pharmacodynamic study expected in Q4 2026 and study initiation in Q1 2027. The FDA's acceptance of historical comparative studies as supportive evidence could reduce the need for a large new efficacy trial, potentially accelerating the BLA timeline. The company's cash runway is limited (~$3.4M pre-offering), so additional financing or warrant exercise may be needed to fund development through the CMAP study.
Price Chart
Executive Summary
AEON Biopharma filed an 8-K furnishing an October 2026 corporate presentation that outlines its strategy to develop ABP-450 as the first clinically substitutable biosimilar to BOTOX® for all 12 therapeutic indications. The presentation highlights FDA Type 2b feedback that provides clarity on the CMAP pharmacodynamic study and allows prior comparative studies to be submitted as supportive evidence, with an IND planned for Q4 2026 and study initiation in Q1 2027. The filing is a routine investor update with no new financial data or material events.
Key Facts
- Developing ABP-450 as a biosimilar to BOTOX® under the FDA's 351(k) pathway targeting all 12 therapeutic indications
- FDA Type 2b meeting (Q3 2026) agreed in principle with the proposed CMAP dose-finding approach and indicated historical comparative studies may be submitted as supportive evidence with appropriate scientific bridging
- IND submission for CMAP pharmacodynamic study planned in Q4 2026; study initiation expected in Q1 2027
- ABP-450 shares the same 900 kDa toxin as Jeuveau® (marketed by Evolus, Inc., $272.3M sales in 2025), manufactured by Daewoong in an FDA-inspected cGMP facility
- 100% amino acid sequence identity to BOTOX® across all 5 proteins of the 900 kDa complex, with identical formulation composition
- Highly similar potency to BOTOX® across LD50 and CBPA assays (ABP-450 avg 98.9 vs BOTOX® 93.9 for LD50; ABP-450 avg 95.3 vs BOTOX® 90.4 for CBPA)
- Cash of approximately $3.4M as of June 30, 2026; gross proceeds of approximately $15.3M from July 2026 underwritten public offering
- Shares outstanding of approximately 18.4M; pre-funded warrants of ~48.2M; time-based warrants of ~49.9M (weighted avg exercise price $4.97); milestone-based warrants of ~98.2M (weighted avg exercise price $0.35)
- U.S. therapeutic botulinum toxin market valued at $3.5B in 2026, growing at 7.7% CAGR to $5.1B by 2031; BOTOX® held ~92% market share in 2025
Financial Impact
No new financial data or guidance provided. Cash position of ~$3.4M as of June 30, 2026, supplemented by ~$15.3M gross proceeds from July 2026 offering. Milestone warrants could provide additional ~$34M capital opportunity if exercised.
Risk Factors
- ABP-450 has not been approved by the FDA for any therapeutic indication; biosimilar approval is uncertain and may require additional studies
- Limited cash runway of ~$3.4M as of June 30, 2026, with significant dilution risk from ~98.2M milestone warrants at $0.35 exercise price
- Dependence on Daewoong Pharmaceutical for manufacturing and supply; any disruption could delay development
- Potential delisting risk from NYSE American if compliance is not maintained
- Competition from existing branded neurotoxins (Xeomin®, Daxxify®, Dysport®) and potential future biosimilars
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001837607-26-000071 |
| Document: aeon-20261023x8k.htm | 0001837607-26-000071 |
| Document: 0001837607-26-000071-index-headers.html | 0001837607-26-000071 |
| Document: 0001837607-26-000071-index.html | 0001837607-26-000071 |
| Document: 0001837607-26-000071.txt | 0001837607-26-000071 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $0.2399 | awaiting T+5 | — | $0.2400 (+0.04%) |
Sep 30, 2026 26d ago | 8-K | $0.3000 $0.3110 | ▲ +3.67% | ▲ +1.75% | $0.2400 (−20.00%) |
Aug 21, 2026 9w ago | 3 | $0.1974 $0.2959 | ▲ +49.90% | ▲ +49.43% | $0.2400 (+21.58%) |
Aug 19, 2026 9w ago | Press Release | $0.1980 $0.2515 | ▲ +27.02% | ▲ +27.41% | $0.2400 (+21.21%) |
Aug 12, 2026 10w ago | Press Release | $0.2706 $0.1931 | ▼ −28.64% | ▼ −26.68% | $0.2400 (−11.31%) |
Jul 23, 2026 13w ago | 8-K | $0.2507 $0.2552 | ▼ −1.79% | ▼ −1.42% | $0.2400 (+4.27%) |
Jul 15, 2026 14w ago | 8-K | $0.2974 $0.2600 | ▲ +12.58% | ▲ +10.91% | $0.2400 (+19.30%) |
Jul 15, 2026 14w ago | 424B4 | $0.2997 $0.2752 | ▲ +8.17% | ▲ +7.19% | $0.2400 (+19.92%) |
Jul 14, 2026 14w ago | EFFECT | $0.3570 $0.2890 | ▲ +19.05% | ▲ +17.75% | $0.2400 (+32.77%) |
Jul 9, 2026 15w ago | S-1/A | $0.5027 $0.2974 | ▲ +40.84% | ▲ +40.71% | $0.2400 (+52.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers